RPRX earnings date and last-quarter result: last quarter beat, P/E 23.83. Updated 2026-07-23.
Royalty Pharma (RPRX) Research Hub
Royalty Pharma (RPRX) trades on NASDAQ, US in the Healthcare (Medical - Pharmaceuticals) sector. As of 2026-10-26, shares last closed at 64.76 USD (+1.41%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 23.83, market cap 25.02B. This hub links to the full technical, earnings and options research available for RPRX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Pharmaceuticals) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 64.76 USD (+1.41%) |
| 52-week range | 52.89 USD – 65.35 USD |
| Trend regime | Range |
| 14-day RSI | 81 (Overbought) |
| Trailing P/E | 23.83 |
| Market cap | 25.02B |
| Dividend yield | 1.55% |
Available research for RPRX
Covered Call on RPRX: how it works, illustrative setup around the real 64.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RPRX: how it works, illustrative setup around the real 64.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RPRX: how it works, illustrative setup around the real 64.76 USD price, max profit/loss, breakeven and when to use it. Educational.
RPRX technical analysis: range, last 64.76 USD, RSI 81, 52w range 52.89 USD–65.35 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is RPRX in?
Royalty Pharma (RPRX) is classified under Healthcare (Medical - Pharmaceuticals), listed on NASDAQ, US.
Is RPRX in an uptrend or downtrend?
As of 2026-10-26, RPRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RPRX's trailing P/E ratio?
RPRX's trailing P/E is 23.83, with a market cap of 25.02B. See the earnings research page for full valuation detail.